VVPR: 119% | VivoPower Secures Amendment And Extension To $34M Shareholder Loan Financing Agreement Following Negotiations With Independent Directors Of AWN Holdings Limited
VRPX: 84% | Virpax Announces Results For A Swine Model Pilot Study For Probudur, Virpax's Long-acting Liposomal Bupivacaine Formulation Injected At A Wound Site To Provide Both Immediate And Extended Pain Relief
LGVN: 52% | Longeveron Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation For Treatment Of Mild Alzheimer's Disease